免疫治疗再挑战在子宫内膜癌与宫颈癌中的疗效
二次免疫治疗后EC客观缓解率27.8%、CC为14.3%,疾病控制率分别为55.6%和64.3%,EC中位无进展生存期8.1个月、CC为9.7个月,3/4级免疫相关不良事件发生率20.0%。
要点
- 复发性EC和CC患者再次免疫治疗仍可见临床活性
- EC二次免疫后客观缓解率27.8%,CC为14.3%
- 二次免疫治疗期间3/4级免疫相关不良事件发生率为20.0%
核心结论
- 既往接受过免疫治疗的复发性子宫内膜癌和宫颈癌患者中,再次免疫治疗在部分患者中显示出临床活性,超过半数患者获得疾病控制。
主要发现
- 二次免疫治疗后EC客观缓解率为27.8%,CC为14.3%。
- 二次免疫治疗后EC疾病控制率为55.6%,CC为64.3%。
- 二次免疫治疗后EC中位无进展生存期为8.1个月,CC为9.7个月。
- 二次免疫治疗期间3/4级免疫相关不良事件发生率为20.0%。
临床怎么用
- 对于既往接受过免疫治疗的复发性子宫内膜癌或宫颈癌患者,再次免疫治疗可作为部分选择患者的治疗选项,但需关注免疫相关毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE(S): As immunotherapy (IO) is increasingly utilized for treatment of endometrial cancer (EC) and cervical cancer (CC), optimal treatment strategies after IO remains poorly defined. We evaluated clinical outcomes, treatment patterns, toxicity, and survival among patients with recurrent EC and CC who received IO after prior IO. METHODS: An Institutional Review Board approved, single-institution retrospective cohort study was conducted among patients with recurrent EC or CC treated with subsequent IO between January 1, 2017, and January 1, 2025. Patients were included if they received at least one dose of IO after prior IO. Clinical characteristics, immune-related adverse events, response, progression-free survival (PFS), and overall survival (OS) were abstracted from the electronic medical record. RESULTS: Of fifty eligible patients, 36 had EC and 14 had CC. Pembrolizumab was the most common first IO agent in both cohorts. Second IO regimens differed by disease site, with pembrolizumab plus lenvatinib most common in EC and pembrolizumab alone most common in CC. Following second IO exposure, objective response rate was 27.8% for EC and 14.3% for CC, while disease control rate was 55.6% and 64.3%, respectively. Median PFS with second IO exposure was 8.1 months in EC and 9.7 months in CC. Grade 3/4 immune-related adverse events occurred in 20.0% during second IO. CONCLUSIONS: IO retreatment demonstrated clinical activity in selected patients with recurrent EC and CC after prior IO, with disease control achieved in more than half of patients. Prospective studies are needed to define optimal patient selection and post-IO treatments.
引用
- Chalif J, Morton M, O'Connor R, et al. A second chance? Outcomes of immunotherapy retreatment after prior checkpoint inhibitor exposure in endometrial and cervical cancer. Gynecol Oncol. 2026. PMID: 42868630. doi:10.1016/j.ygyno.2026.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。